Significant recent events in 2009 included: * In January 2009, we completed the six-patient Phase I clinical trial of our HuCNS-SC[R] product candidate as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), also often referred to as Batten disease.
In January 2008, the Company completed enrollment and dosing of a six-patient Phase I clinical trial of its proprietary HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital.
Highlights for 2007 and significant events since the end of the year include: * In January 2008, we completed enrollment and dosing of a six-patient Phase I clinical trial of our HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital.
This study is designed to evaluate the safety and preliminary efficacy of HuCNS-SC as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, or Batten disease).
NASDAQ: STEM) which is designed to evaluate the safety and preliminary efficacy of HuCNS-SC[TM] as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL).
This transplant is the first of six that are planned as part of the Company's Phase I clinical trial designed to evaluate the safety and preliminary efficacy of HuCNS-SC as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL).
The Company is currently conducting a Phase I clinical trial of its proprietary human neural stem cells (HuCNS-SC[TM]) for the treatment of infantile and late infantile neuronal ceroid lipofuscinosis (NCL).
The Company is currently conducting a Phase I clinical trial of its proprietary human neural stem cells (HuCNS-SC(TM)) for the treatment of infantile and late infantile neuronal ceroid lipofuscinosis (NCL).
